188 related articles for article (PubMed ID: 22135137)
1. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study.
Bonora S; Calcagno A; Cometto C; Fontana S; Aguilar D; D'Avolio A; Gonzalez de Requena D; Maiello A; Dal Conte I; Lucchini A; Di Perri G
Infection; 2012 Feb; 40(1):69-75. PubMed ID: 22135137
[TBL] [Abstract][Full Text] [Related]
2. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
[TBL] [Abstract][Full Text] [Related]
3. Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Joly V; Fagard C; Grondin C; Descamps D; Yazdanpanah Y; Charpentier C; Colin de Verdiere N; Tabuteau S; Raffi F; Cabie A; Chene G; Yeni P;
Antimicrob Agents Chemother; 2013 Feb; 57(2):758-65. PubMed ID: 23165467
[TBL] [Abstract][Full Text] [Related]
4. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
[TBL] [Abstract][Full Text] [Related]
5. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).
Gripshover BM; Ribaudo H; Santana J; Gerber JG; Campbell TB; Hogg E; Jarocki B; Hammer SM; Kuritzkes DR;
Antivir Ther; 2006; 11(5):619-23. PubMed ID: 16964830
[TBL] [Abstract][Full Text] [Related]
6. A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
Ruane P; Alas B; Ryan R; Perniciaro A; Witek J
AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1215-9. PubMed ID: 21083412
[TBL] [Abstract][Full Text] [Related]
7. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
Reynes J; Arastéh K; Clotet B; Cohen C; Cooper DA; Delfraissy JF; Eron JJ; Henry K; Katlama C; Kuritzkes DR; Lalezari JP; Lange J; Lazzarin A; Montaner JS; Nelson M; O' Hearn M; Stellbrink HJ; Trottier B; Walmsley SL; Buss NE; Demasi R; Chung J; Donatacci L; Guimaraes D; Rowell L; Valentine A; Wilkinson M; Salgo MP
AIDS Patient Care STDS; 2007 Aug; 21(8):533-43. PubMed ID: 17711378
[TBL] [Abstract][Full Text] [Related]
8. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
Poveda E; Rodés B; Labernardière JL; Benito JM; Toro C; González-Lahoz J; Faudon JL; Clavel F; Schapiro J; Soriano V
J Med Virol; 2004 Sep; 74(1):21-8. PubMed ID: 15258964
[TBL] [Abstract][Full Text] [Related]
9. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
Youle M; Staszweski S; Clotet B; Arribas JR; Blaxhult A; Carosi G; Dejesus E; Di Perri G; Estrada V; Fisher M; Kovacs C; Kulasegaram R; Lazzarin A; Marriott D; Muñoz L; Reynes J; Shalit P; Slim J; Tsoukas C; Vaccaro A; Vera J
HIV Clin Trials; 2006; 7(2):86-96. PubMed ID: 16798623
[TBL] [Abstract][Full Text] [Related]
10. A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study.
Clotet B; Capetti A; Soto-Ramirez LE; Gatell JM; Rowell L; Salgo M; Schapiro JM
J Antimicrob Chemother; 2008 Dec; 62(6):1374-8. PubMed ID: 18782780
[TBL] [Abstract][Full Text] [Related]
11. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
[TBL] [Abstract][Full Text] [Related]
12. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
Ruof J; Dusek A; DeSpirito M; Demasi RA
Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
[TBL] [Abstract][Full Text] [Related]
13. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M
HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
[TBL] [Abstract][Full Text] [Related]
14. Adherence to enfuvirtide and its impact on treatment efficacy.
Rockstroh J; Dejesus E; Donatacci L; Wat C; Bertasso A; Labriola-Tompkins E; Shikhman A; Atkins B; Guimaraes D; Wilkinson M; Thommes J; Rowell L; Demasi R; Salgo M
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):141-8. PubMed ID: 18240965
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen.
Cohen CJ; Clumeck N; Molina JM; Thompson M; Patel K; Wintfeld N; Green J
J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1140-6. PubMed ID: 15319673
[TBL] [Abstract][Full Text] [Related]
16. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Nelson M; Arastéh K; Clotet B; Cooper DA; Henry K; Katlama C; Lalezari JP; Lazzarin A; Montaner JS; O'Hearn M; Piliero PJ; Reynes J; Trottier B; Walmsley SL; Cohen C; Eron JJ; Kuritzkes DR; Lange J; Stellbrink HJ; Delfraissy JF; Buss NE; Donatacci L; Wat C; Smiley L; Wilkinson M; Valentine A; Guimaraes D; Demasi R; Chung J; Salgo MP
J Acquir Immune Defic Syndr; 2005 Dec; 40(4):404-12. PubMed ID: 16280694
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
19. Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load.
Vaidya NK; Rong L; Marconi VC; Kuritzkes DR; Deeks SG; Perelson AS
PLoS Comput Biol; 2010 Nov; 6(11):e1001012. PubMed ID: 21124866
[TBL] [Abstract][Full Text] [Related]
20. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
